BiographyDr. Yeh is a graduate of Harvard Medical School, and has also received graduate degrees in health policy from the London School of Hygiene and Tropical Medicine/Economics (jointly) and business administration from Oxford University. He completed residency at the MGH, cardiology fellowship at the University of California, San Francisco, and interventional cardiology fellowship at the MGH. Dr. Yeh is a member of the interventional cardiology staff, focusing on coronary interventional procedures, including transradial catheterization and recanalization of chronic total occlusions (CTO). He is the Co-Director of the MGH CTO Intervention Program, and specializes in complex coronary procedures involving retrograde and antegrade dissection-reentry techniques.
His research examines real world outcomes and the comparative effectiveness of novel cardiovascular devices and therapies, in collaboration with faculty at the Department of Health Care Policy at Harvard Medical School. He also serves as Medical Director for Trial Design at the Harvard Clinical Research Institute, where he is involved in the design of clinical trials and post-marketing studies of cardiovascular devices. Dr. Yeh's research is funded by a K23 career development award from the National Heart, Lung and Blood Institute, as well as the American Heart Association, the Harvard Clinical Research Institute, and the Hassenfeld Scholars Program.
In General awards and honors
February is American Heart Month, and the spotlight is on heart health. Throughout this month, we will be featuring articles including discussions with physicians in the Massachusetts General Heart Center to learn more about the topics surrounding heart disease, the leading cause of death in the U.S. for both men and women.
New treatment option allows some coronary artery patients to "bypass" bypass surgery. Interventional cardiologists at the Institute for Heart, Vascular and Stroke Care at Mass General offer a less-invasive treatment with quicker recovery.
A new study finds that the use of drug-eluting stents after angioplasty bears little relationship to patients' predicted risk of restenosis (reblockage) of the treated coronary artery, the situation the devices are designed to prevent.